{
    "clinical_study": {
        "@rank": "109066", 
        "arm_group": [
            {
                "arm_group_label": "Travoprost", 
                "arm_group_type": "Experimental", 
                "description": "Travoprost ophthalmic solution 0.004% (new formulation), one drop administered in each eye once daily at 9 PM (\u00b1 30 minutes)"
            }, 
            {
                "arm_group_label": "Timolol", 
                "arm_group_type": "Active Comparator", 
                "description": "Timolol ophthalmic solution, 0.5%, one drop administered in each eye twice daily at 9 AM (\u00b1 30 minutes) and 9 PM (\u00b1 30 minutes)"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to demonstrate that the IOP-lowering efficacy of\n      Travoprost ophthalmic solution, 0.004% (new formulation) is noninferior to Timolol\n      ophthalmic solution (0.5% or 0.25%) in pediatric glaucoma patients."
        }, 
        "brief_title": "Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Pediatric Glaucoma", 
            "Elevated Intraocular Pressure (IOP) in Pediatric Patients"
        ], 
        "condition_browse": {
            "mesh_term": "Glaucoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  2 months to <18 years of age.\n\n          -  Diagnosis of pediatric glaucoma.\n\n          -  Qualifying mean IOP at the Eligibility Visit in at least one eye.\n\n          -  Written informed consent, including assent when applicable, MUST be obtained from the\n             parent or legally authorized representative prior to any procedure specified in the\n             protocol,including screening procedures.\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Females of childbearing potential who are pregnant, intend to become pregnant during\n             the study period, are breast feeding, or are not using any form of birth control\n             measures.\n\n          -  History of chronic, recurrent or severe inflammatory eye disease.\n\n          -  Ocular trauma requiring medical attention within the past 3 months prior to the\n             Screening Visit.\n\n          -  Ocular infection or ocular inflammation within the past 30 days prior to the\n             Screening Visit.\n\n          -  Clinically significant or progressive retinal disease.\n\n          -  Severe ocular pathology (including severe dry eye) in the opinion of the Investigator\n             that would preclude the administration of a topical prostaglandin analog or a topical\n             beta-blocker.\n\n          -  Intraocular surgery within the past 30 days in the study eye prior to the Screening\n             Visit.\n\n          -  Any abnormality preventing reliable applanation tonometry.\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "2 Months"
        }, 
        "enrollment": {
            "#text": "184", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01652664", 
            "org_study_id": "C-12-008"
        }, 
        "intervention": [
            {
                "arm_group_label": "Travoprost", 
                "intervention_name": "Travoprost ophthalmic solution, 0.004% (new formulation)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Timolol", 
                "description": "Timolol ophthalmic solution, 0.5%", 
                "intervention_name": "Timolol ophthalmic solution, 0.5%", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Timolol", 
                "Travoprost", 
                "Cloprostenol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact the Alcon Call Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Mean Intraocular pressure (IOP) change from baseline to Month 3 in the study eye.", 
            "safety_issue": "Yes", 
            "time_frame": "3 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01652664"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}